Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Pieda Study: Retacrit vs Epogen in CKD Anemia
NCT02504294Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2015
- Primary completion
- Jul 2016
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in anemia of chronic kidney disease (CKD-A) comparing Epoetin Hospira Arm with Standard of Care Arm (2 arms). Primary endpoint: Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL). Started Jul 2015; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02504294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504294.